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Abstract
Introduction: The current medical literature has conflicting results about fac-
tors related to hypothyroidism and nodular recurrences during follow-up of
hemithyroidectomized patients. We aimed to evaluate factors that may have
a role in new nodule formation, hypothyroidism, increase in thyroid lobe and
increase in nodule volumes in these patients with and without Hashimoto’s thy-
roiditis (HT), and with and without levothyroxine (LT4) use.
Material and methods: We enrolled 140 patients from five different hospitals in
Ankara and evaluated their thyroid tests, autoantibody titre results and ultra-
sonographic findings longitudinally between two visits with a minimum 6-month
interval.
Results: In patients with HT there was no significant difference between the
two visits but in patients without HT, thyroid stimulating hormone (TSH) levels
and nodule volume were higher, and free T4 levels were lower in the second
visit. Similarly, in patients with LT4 treatment there was no difference in TSH,
free T4 levels, or lobe or nodule size between the two visits, but the patients
without LT4 had free T4 levels lower in the second visit. Regression analysis
revealed a relationship between first visit TSH levels and hypothyroidism dur-
ing follow-up. 
Conclusions: Patients who have undergone hemithyroidectomy without LT4
treatment and without HT diagnosis should be followed up more carefully for
thyroid tests, new nodule formation and increase in nodule size. The TSH lev-
els at the beginning of the follow-up may be helpful to estimate hypothyroidism
in hemithyroidectomized patients. 
Key words: hemithyroidectomy, hypothyroidism, nodular goitre, Hashimoto’s 
disease, thyroid lobectomy.
Introduction
Thyroid nodules are one of the most frequent endocrinological problems
in the adult population [1, 2]. The use of fine needle aspiration biopsy (FNA)
Corresponding author:
Sibel Ertek MD, PhD
Endocrinology and Metabolic
Diseases Department
Ufuk University 
Medical Faculty
Dr. R. Ege Hospital
Mevlana Bulvari (Konya Yolu)
No: 86-88 Balgat
Ankara, Turkey
Phone: +90 312 204 40 00
Fax: +90 312 204 40 55
E-mail: sibelertek@yahoo.it 
Clinical research
1Department of Endocrinology and Metabolic Diseases, Dr. R. Ege Hospital, Ufuk
University Medical Faculty, Ankara, Turkey
2Department of Endocrinology and Metabolic Diseases, Ataturk Hospital, Ankara, Turkey 
3Department of Endocrinology and Metabolic Diseases, Baskent University Hospital,
Ankara, Turkey
4Department of Endocrinology and Metabolic Diseases, Ibni Sina Hospital, Ankara
University Medical Faculty, Ankara, Turkey
5Department of Endocrinology and Metabolic Diseases, Numune Hospital, Ankara, Turkey
Submitted: 8 October 2011
Accepted: 14 November 2011
Arch Med Sci 2012; 8, 2: 263-269
DOI: 10.5114/aoms.2012.28222
Copyright © 2012 Termedia & Banach264 Arch Med Sci 2, April / 2012
S. Ertek, R.Ü. Ersoy, C. AnIl, Ö. Demir, M.F. Erdog ˘an, S. Güllü, D. Berker, K. Gül, U. Ünlütürk, G. Erdog ˘an; Ankara Thyroid Study Group
gives clues prior to surgical intervention about pathol-
ogy of the nodule [3], and improved ultrasonographic
techniques provide better evaluation of the whole
thyroid parenchyma. Therefore, surgical interventions
aimed at saving the nodule-free part of the thyroid
parenchyma are increasingly employed, to avoid
postoperative hypothyroidism and complications of
bilateral surgical techniques [4, 5].
Thyroid lobectomy or hemithyroidectomy has
advantages over total thyroidectomy [4-6] for soli-
tary nodules but it comes with the risk of nodule
recurrence [4-6]. Nodule recurrence may be prob-
lematic during follow-up, particularly in patients
who are found to have carcinoma at postopera-
tive pathological evaluation [4-6]. Higher risk of
nodule recurrence or risk of hypothyroidism after
hemithyroidectomy, increase in remaining thyroid
lobe volume and/or nodule volume and benefits
of levothyroxine (LT4) use in these patients remain
unclear [6-11]. Meanwhile, the role of iodine defi-
ciency or the effects of successful iodization (as
in Turkey) on nodule recurrence after hemithy-
roidectomy still remain unknown [12, 13]. Iodine
intake may have effects in Hashimoto thyroiditis
(HT) [14]. It is also not clear whether presence of
HT may have an impact on nodular recurrence in
these patients.
In the present study we sought the risk factors
that may be associated with nodular recurrence,
hypothyroidism, increase in thyroid lobe or nodule
volume in patients with or without HT, and in
patients on and not on LT4 use, by evaluation of
longitudinal data of patients who had undergone
hemithyroidectomy.
Material and methods
We enrolled 140 patients (27 men, 113 women)
within ages 18-80 years from five different hos-
pitals in Ankara. We included patients who had
undergone hemithyroidectomy and had records
of two different visits which were separated by
at least 6 months duration. Patients with a his-
tory of multiple thyroid operations, radioactive
iodine treatment, patients who were receiving
drugs for other ailments that may affect thyroid
functions (such as amiodarone or steroids),
hypophyseal pathologies, patients with renal
impairments and patients who had changes in
the drug regimen between the 2 visits were
excluded. Second visit measurements were
accepted if they were a minimum of 3 months
after the surgery, to exclude effects of postoper-
ative oedema and thyroid function variations. The
interval between the two visits was 30.6 ±9.7
months. All patients were informed about the
study and all provided written informed consent
before their evaluation. The study was approved
by the Ethical Committee of Ufuk University as
the main centre and carried out following the
principles of the Helsinki Conference. 
We collected data on the pre- and postoperative
diagnosis at the first visit, on thyroid function tests
(TSH, free T4 and free T3), serum thyroid autoanti-
bodies, LT4 use, remaining lobe volume, and nod-
ule volumes on ultrasonography at both visits, and
assessed for the presence and/or appearance of
new nodules on the second visit. Nodules were
defined as > 3 mm diameter on ultrasonography in
all three dimensions and ultrasonographic thyroid
evaluation was made by the same endocrinologists
educated by the same thyroid centre. Increase in
nodule volume was defined as > 20% increase in
at least two dimensions of the nodule and increase
in lobe volume was defined as > 10% increase in
lobe volume across the study interval [15, 16].
Hypothyroidism was defined as serum TSH ≥ 5 mIU/
ml, including subclinical hypothyroidism.
For diagnosis of HT, we accepted pathological
examination of operated thyroid lobe parenchyma. 
Hormonal measurements and thyroid 
autoantibodies
Thyroid function tests (TSH, free T4, free T3) were
measured by electrochemiluminescence immunoas-
say (ECLIA) Immulite 2000 (Diagnostic Products
Corp, Los Angeles, CA, USA) and Abbot Architect
2000 in four hospitals and by the same method,
and by Elecsys 170® in one hospital. Measured TSH
levels were recorded as mIU/ml and free T4 and
free T3 as pmol/l to have the same SI (Syste `me
International d'Unités) units. Thyroid autoantibod-
ies were measured by the competitive radioim-
munoassay (RIA) method (using Brahms® Dynotest)
in one hospital, by the ECLIA method using Roche
Elecsys 2010 in another hospital, and by the ECLIA
method using Abbott Architect 2000 in three oth-
er hospitals. Interchangeability of Roche Elecsys
2010 and Abbot Architect 2000 measurements was
tested before starting the study.
Ultrasonographic evaluation
Three university hospitals used General Electric®
Logiq 5000 and a 9 mHz linear probe, and two hos-
pitals used Esaote Colour Doppler US (MAG Tech-
nology Co, Ltd. Model: 796FDII Yung-ho City, Taipei;
Taiwan) ultrasonography and a 9 mHz linear probe
and General Electric Logiq 400 and an 11 mHz lin-
ear probe. Three dimensions of the thyroid gland
were recorded and thyroid and nodule volumes
were calculated by the formula “length X height X
depth X pi/6” as ml [17]. Ultrasonographic evalua-
tions were performed by endocrinologists who had
ultrasonography education from the same centre
(Ankara University, Endocrinology and Metabolic
Diseases Department).Arch Med Sci 2, April / 2012 265
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Statistical analysis
Differences in the test results between the two
visits were compared using the Wilcoxon signed
rank test by presence of HT, by gender, and by LT4
use. Factors found in bivariate analyses to be asso-
ciated with hypothyroidism (increase in nodule
number and volume, increase in thyroid volume)
were evaluated by multivariate logistic regression
analysis, using the program SPSS 16.0. Two-sided
statistical significance was considered if the p val-
ue was < 0.05. For evaluation of increase in nod-
ule size we compared the size of each nodule
(there were 4 nodules maximum) between the two
visits. 
Results
Among 140 patients 27 (19.3%) were male, 
113 (80.7%) were female, and mean age (± SD) was
52.7 (±11.9) years. Postoperative pathological exam-
ination revealed HT in 40 patients (28.6%). Inci-
dence of HT (p = 0.018) and the anti-TPO antibody
levels (p = 0.004 at first visit and p = 0.035 at sec-
ond visit) were higher in women (Table I). 
Thyroid tests and ultrasonography in HT 
and non-HT groups
Comparison of thyroid tests and ultrasono-
graphic evaluation between the two visits in HT and
non-HT patients are summarized in Table II. There
were no differences between the two visits among
patients with HT, whereas in patients without HT,
TSH was higher at the second visit (p = 0.042), free
T4 was lower (p = 0.001), number of nodules was
higher (p = 0.005) and nodule sizes were increased
with a slight statistically significant difference 
(p = 0.043) (Figures 1 and 2). However, when we
compared the two visits using the clinical signifi-
cance definitions (i.e. > 20% increase in nodule vol-
ume and > 10% increase in remaining lobe volume)
those differences were not significant (for nodule
size p = 0.523 and for lobe size p = 0.329).
Among these patients with HT 11 (27.5%) were
having LT4 treatment, and among the patients with-
out HT, 39 (39%) were taking LT4.
Thyroid tests and ultrasonography in patients
with and without LT4 use
Ultrasonography findings and thyroid tests of
patients were compared separately between the
two visits by LT4 use (Table III). There was no sig-
nificant difference between the two visits in
patients on LT4 treatment, but in patients not on
LT4, free T4 was significantly lower at the second
visit (p = 0.001) and nodule size had increased in
one nodule slightly (p = 0.043). There was an
increase in nodule number but statistical tests did
not reveal significance (p = 0.055). For clinical sig-
Parameter Female Male  All patients  Difference 
(mean ± SD) (mean ± SD) (mean ± SD) (value of p)*
Age [years] 51.5 ±11.36 57.2 ±13.4 52.6 ±11.96 0.712
Hashimoto thyroiditis [%] 32.7 11.1 28.6 0.018*
LT4 use [%] 83.8 16.2 48.6 0.245
1st visit TSH [mIU/ml] 3.2 ±3.19 1.42 ±1.16 2.85 ±2.62 0.063
1st visit sT3 [pmol/l] 3.67 ±1.04 4.33 ±1.35 3.80 ±1.13 0.172
1st visit sT4 [pmol/l] 16.03 ±3.72 16.74 ±4.15 16.17 ±3.81 0.623
1st visit anti-TG 69.18 ±63.31 20.88 ±16.04 60.25 ±53.44 0.246
1st visit anti-TPO 56.30 ±42.5 11.97 ±8.50 47.06 ±28.05 0.004*
2nd visit TSH 4.29 ±3.45 2.15 ±1.95 3.88 ±2.92 0.583
2nd visit sT3 3.71 ±1.49 3.73 ±0.94 3.71 ±1.39 0.587
2nd visit T4 14.62 ±4.34 14.92 ±3.41 14.68 ±4.17 0.697
2nd visit anti-TG 78.30 ±76.12 21.46 ±19.70 68.13 ±64.01 0.865
2nd visit anti-TPO 63.74 ±60.21 13.17 ±14.10 53.85 ±45.03 0.035*
1st visit nodule no. 0.89 ±0.79 1.00 ±0.97 0.91 ±0.89 0.685
2nd visit nodule no. 1.15 ±1.18 1.00 ±1.33 1.12 ±1.20 0.784
1st visit remaining lobe volume [ml] 9.8 ±8.2 12.0 ±9.11 10.2 ±8.4 0.816
2nd visit remaining lobe volume [ml] 9.2 ±9.1 11.95 ±8.22 9.78 ±9.07 0.017*
SD – standard deviation, *statistically significant (p < 0.05)
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Figure 1. Comparison between two visits regarding TSH levels, in HT vs. non-HT, on LT4 vs. not on LT4 groups
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Figure 2. Comparison between two visits regarding number of nodules, in HT vs. non-HT, on LT4 vs. not on LT4 groups
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*p < 0.05, **Nodule volumes are calculated in millilitres (ml)
Parameter Hashimoto (+) Hashimoto (–)
1st visit 2nd visit Value of p 1st visit 2nd visit Value of p* 
TSH [mIU/ml] 5.93 ±5.81 8.58 ±7.57 0.835 1.72 ±1.07 2.00 ±1.47 0.042*
sT4 [pmol/l] 15.66 ±4.01 14.73 ±5.34 0.122 16.38 ±3.72 14.65 ±3.61 0.001*
sT3 [pmol/l] 3.85 ±1.22 3.94 ±2.11 0.641 3.78 ±1.10 3.62 ±0.93 0.394
Anti-TG 159.53 ±151.17 214.95 ±207.29 0.491 13.67 ±6.61 15.7 ±7.97 0.412
Anti-TPO 125.14 ±112.17 174.53 ±157.54 0.761 12.26 ±7.52 13.62 ±11.07 0.736
Remaining lobe volume** 9.15 ±7.94 8.78 ±7.94 0.554 10.69 ±8.62 10.17 ±7.71 0.811
Number of nodules 0.65 ±0.83 0.65 ±0.92 0.776 1.02 ±1.01 1.3 ±1.27 0.005*
Nodule 1 volume 9.8 ±2.7 10.5 ±2.6 0.494 9.0 ±3.7 9.6 ±3.8 0.135
Nodule 2 volume 3.7 ±2.2 4.2 ±2.8 0.515 2.0 ±1.5 2.2 ±1.8 0.209
Nodule 3 volume 2.9 ±1.2 2.8 ±2.0 0.109 3.7 ±1.7 3.9 ±1.4 0.136
Nodule 4 volume** 2.1 ±1.0 2.0 ±1.0 0.981 2.03 ±2.0 2.52 ±1.9 0.043*
Table II. Comparison of thyroid tests and ultrasonographic findings in HT and non-HT patients for two successive
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nificance the two groups were compared (by χ2
test) and neither nodule size (p = 0.588) nor
remaining lobe volume (p = 0.513) was statistical-
ly or clinically different. 
Factors related to hypothyroidism, number 
of nodules, increase in nodule and remaining
lobe volumes
We evaluated the role of age, gender, presence
of HT, LT4 use and TSH value at the first visit on
hypothyroidism at the second visit. Only the TSH
value at the first visit was associated with hypothy-
roidism (p = 0.035, exp(B) = 1.083, 95% CI: 1.006-
1.167). The same parameters were also tested for
increase in number of nodules, for nodule size and
for remaining lobe volume (by logistic regression
analysis) and none of them were significantly relat-
ed (p > 0.05).
Discussion
Partial thyroidectomies provide some advantages
to the patient, for example they are associated with
lower incidence of hypothyroidism and lower risks
of surgical complications. Risk of chronic hypothy-
roidism was found to be 87% in subtotal and 46%
in hemithyroidectomies compared to 100% in total
thyroidectomies [4]. Hemithyroidectomy also
lessens the risk of hypocalcaemia and recurrent
laryngeal nerve injury, but with a risk of nodule
recurrence [5, 6]. The medical literature provides
conflicting findings with regard to the factors asso-
ciated with hypothyroidism and formation of new
nodules, and the need for LT4 use to prevent recur-
rences. In the study by Niepomniszcze et al., 47
women with hemithyroidectomy due to follicular
adenoma were evaluated with palpation for 7 years
and they found 32% new nodule and goitre forma-
tion in patients without LT4 use [7]. In another
study by Bellantone et al. evaluating patients with
unilateral toxic nodular goitre, LT4 use decreased
the recurrence of nodules [8], whereas Waldström
et al. did not find any benefit of LT4 use in multin-
odular goitre patients after hemithyroidectomy [9].
In our study we did not find a relationship between
number of nodules, nodule volume, lobe volume
and LT4 use or HT. But when we compared patients
on LT4 treatment with those not on LT4, patients
not on LT4 treatment had lower free T4 and it
resulted in a statistically significant (but not clini-
cally important) increase in nodule volume at the
second visit. Thus, we suggest that patients, par-
ticularly those not on LT4 treatment, should be fol-
lowed closely for nodule enlargement and new nod-
ule formation.
Wolmard et al. suggested the importance of
starting TSH levels (> 1.6 μU/ml) and lymphocytic
infiltration in thyroid parenchyma to predict risk of
hypothyroidism in these patients [18]. Like
Wormald et al., in our study, baseline TSH levels
were significantly associated with hypothyroidism.
However, in our study, patients with HT did not
have a significant increase in TSH and number of
nodules in the follow-up visit, while among those
without HT patients had a significant increase in
TSH and number of nodules. It is known that
patients with nodular goitres may be predisposed
to clonal or polyclonal nodular recurrence tenden-
cy [19] but in HT, lymphocytic infiltration and atro-
phy of the gland [20] may be the reason for the
lower number of nodules.
There is also a debate on LT4 use for the pre-
vention of nodule formation in the remaining thy-
roid lobe after a partial thyroidectomy. Alba et al.
followed 223 patients and they found less nodular
recurrence among patients with LT4 use [21]. Yetkin
et al. reported that the nodular recurrence was
associated with multinodularity, specific histopatho-
*p < 0.05, **Nodule volumes are calculated in millilitres (ml)
Parameter Patients on LT4  Patients not on LT4 
1st visit 2nd visit Value of p 1st visit 2nd visit Value of p* 
TSH [mIU/ml] 3.11 ±2.86 5.55 ±4.84 0.251 2.61 ±4.46 2.31 ±1.67 0.109
sT4 [pmol/l] 17.07 ±4.45 16.51 ±4.87 0.053 15.31 ±2.84 13.81 ±3.10 0.001*
sT3 [pmol/l] 3.76 ±1.31 3.44 ±3.11 0.069 3.84 ±0.95 4.03 ±1.75 0.572
Remaining lobe volume** 9.96 ±9.75 9.83 ±9.18 0.274 10.53 ±7.03 9.72 ±6.55 0.329
Number of nodules 0.83 ±0.94 1.01 ±1.01 0.134 0.98 ±1.05 1.22 ±1.36 0.055
Nodule 1 volume** 12.8 ±4.7 13.2 ±4.8 0.274 5.8 ±1.4 6.2 ±1.6 0.288
Nodule 2 volume 8.9 ±2.4 9.4 ±3.5 0.195 2.1 ±1.1 2.0 ±1.4 0.446
Nodule 3 volume 2.8 ±1.4 2.9 ±2.5 0.799 1.4 ±1.2 1.4 ±1.6 0.347
Nodule volume** 1.3 ±1.0 1.3 ±1.1 0.891 2.2 ±2.3 3.1 ±1.1 0.043*
Table III. Comparison of thyroid tests and ultrasonographic findings in patients on and not on LT4 use, for two dif-
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logical characteristics of the nodule and larger pre-
operative volume of the thyroid [10]. In our study
although we found that patients not on LT4 treat-
ment had a larger nodule volume and non-HT
patients had an increased number of nodules,
regression analysis did not reveal any significant
relationship between presence of HT, LT4 use and
nodule number or volume of lobes or nodules.
Our study is the first clinical study to evaluate
nodules and volumes of the remaining lobes among
HT and non-HT patients in an iodine deficient area.
Studies in similar geographic areas are scarce and
have different methodological criteria and/or sur-
gical approaches [8-10]. Limitations of our study
include the possibility of omitting the TSH fluctua-
tions between the two visits due to possible poor
compliance of LT4 in patients with drug use, and
underestimating the effect of TSH on thyroid and/or
nodule volumes. Another limitation is the absence
of knowledge on simultaneous urinary iodine lev-
els of patients, because some patients have tests
before and after iodization in Ankara. Strengths
include the fact that the ultrasonographic evalua-
tions were all made by endocrinology specialists to
provide standardization. An important point is the
absence of the definition of increased lobe volume
in medical literature, although there are defined cri-
teria about increase in nodule volume. For consis-
tency, we accepted more than 10% increase in the
remaining lobe volume as “increase” for lobe eval-
uation. Finally, we cannot extrapolate these results
to other partial thyroidectomies, since we only
included hemithyroidectomized patients. Similarly,
since we excluded patients with a history of multi-
ple thyroid surgical interventions, we cannot make
inferences on pathologies of recurrent nodules fol-
lowing multiple surgical interventions. 
Meanwhile, despite continuing discussions and
studies about benefits of LT4 treatment on nodule
and thyroid volume, the dosage should be titrated
carefully, considering multiple organ systems [22]
and special groups of patients such as pregnant
women [23].
In conclusion, our study revealed that starting
TSH levels at a given time may have some value for
prediction of the risk of hypothyroidism in the
future. Caution is however needed with patients
not on LT4 treatment for thyroid test abnormalities
and in patients without HT diagnosis for the poten-
tial of a modest increase in nodule volume and
increase in TSH levels. There is a need for additional
prospective studies with larger sample sizes and
meta-analyses to further explore risk factors asso-
ciated with hypothyroidism and recurrence after
hemithyroidectomies.
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